YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Different Sizes of Empty Prescription Bottles stock photo] FatCamera/E+ via Getty Images Millions of Americans use mail-order pharmacies from Canada and other countries to personally import medication for a fraction of the U.S. cost. That…
Comparing the Vanguard Health Care ETF (NYSEMKT:VHT) and State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) involves choosing between broad healthcare sector coverage and a concentrated focus on pharmaceutical industry players. These…
The Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) provides broad healthcare exposure at a fraction of the cost of the State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH), which targets a specific industry niche. Investors seeking…
[Patients Receiving Medical Infusions in a Clinical Setting with Nurse Assistance] FatCamera/iStock via Getty Images Earlier this week, shares of Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and partner Merck (MRK [https://seeking…
[Merck & Co. headquarters in Silicon Valley] Sundry Photography/iStock Editorial via Getty Images Earlier this month, President Donald Trump announced an executive order aimed at changing the number and timing of vaccines recommended for c…
Healthcare ETFs are hitting one-year highs because the sector is benefiting from a solid combination of improving earnings visibility, attractive relative valuations, and a rotation out of overcrowded AI/tech trades into defensive growth.…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Short interest data from late July 2026 highlights deeply divided investor sentiment across the healthcare sector. St…
Check out the companies making the biggest moves premarket: AstraZeneca , Bristol Myers Squibb — Shares of the pharmaceutical companies moved in opposite directions after The Financial Times reported that the two were in talks to merger. A…
Investors looking for stability should buy these funds focused on companies with strong sales, healthy dividends, and cash flow. Continue Reading
[Close-Up Shot of Scientists Hands typing Data in Laptop in Laboratory] Tom Werner Rajesh Kumar, head of European Life Sciences & Healthcare Equity Research at HSBC, positioned healthcare (XLV [https://seekingalpha.com/symbol/XLV]) as a de…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The Health Care Select Sector SPDR® Fund ETF (XLV [https://seekingalpha.com/symbol/XLV]), which tracks the health car…
Key Points The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year returns but experienced a much st…
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on May 1, 2006. Retail and institutional…
The Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) and State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) both target healthcare innovation but differ in their diversification levels and cost structures. These two funds provide distin…
Key Points State Street SPDR S&P Pharmaceuticals ETF provides exposure to 65 companies compared to the 25 holdings in VanEck Biotech ETF. VanEck Biotech ETF has experienced a deeper maximum drawdown of almost 40% over the last five years.…
The State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) offers broader exposure and lower historical volatility than the VanEck Biotech ETF (NASDAQ:BBH), which relies on a smaller group of biotechnology leaders. While both funds offer…
* SPDR S&P Pharmaceuticals ETF (XPH [https://seekingalpha.com/symbol/XPH]) - $0.0590 [https://www.ssga.com/us/en/individual/etfs/funds/spdr-sp-pharmaceuticals-etf-xph]. * 30-Day SEC Yield of 0.37% as of June 17. * Payable Jun 24; for share…
The State Street SPDR S&P Pharmaceuticals ETF(NYSEMKT:XPH) offers a lower-cost entry into the drug manufacturing space, while the First Trust NYSE Arca Biotechnology Index Fund(NYSEMKT:FBT) provides concentrated exposure to biotechnology.…
Key Points Invesco Nasdaq Biotechnology ETF features a significantly lower expense ratio and higher trailing-12-month dividend yield than State Street SPDR S&P Pharmaceuticals ETF State Street SPDR S&P Pharmaceuticals ETF offers a more est…
Investors choosing between Invesco Nasdaq Biotechnology ETF(NASDAQ:IBBQ) and State Street SPDR S&P Pharmaceuticals ETF(NYSEMKT:XPH) could weigh the lower costs and broader diversification of IBBQ against the established size and pharmaceut…
[100 US dollar note on a USA flag with word TARIFFS] Tomas Ragina/iStock via Getty Images Approximately $20.6B is on its way to importers who successfully filed claims using the new web portal developed by US Customs and Border Protection,…
A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs? Products that are based on ma…
[Senior woman buying medicine at drugstore] Luis Alvarez The Trump administration plans to impose tariffs on pharmaceutical companies that haven't agreed to lower U.S. drug prices, with an announcement expected as soon as Thursday, _Bloomb…
Quick Read SPDR S&P Pharmaceuticals ETF (XPH) returned 29.44% over one year versus the S&P 500’s 12%. XPH gained only 10.49% over five years while the broader market returned 74.77%. XPH’s equal weighting amplifies impact of clinical trial…
Short interest in small-cap healthcare surged toward the end of January, centering heavily on the biotechnology sector. Data as of January 30 shows that KalVista (KALV [https://seekingalpha.com/symbol/KALV]) and Intellia (NTLA [https://see…
[Young female scientist working in laboratory] Solskin Pharmaceutical (PJP [https://seekingalpha.com/symbol/PJP]), (XPH [https://seekingalpha.com/symbol/XPH]), (PPH [https://seekingalpha.com/symbol/PPH]) and biotechnology stocks (XBI [http…
[Data particle around the Earth which with stock charts in cyber space] Hiroshi Watanabe UBS’s global equity strategy team published a list of 10 ideas challenging consensus views and identifying where core forecasts might miss the mark. I…
* State Street® SPDR® S&P® Pharmaceuticals ETF (XPH [https://seekingalpha.com/symbol/XPH]) declares $0.113/share quarterly dividend [https://www.ssga.com/us/en/intermediary/resources/documents/etf-dividend-distributions]. * 30-Day SEC Yiel…
Despite Wall Street’s fascination with AI-driven gains, underlying economic signals reveal a more fragile scenario for everyday consumers. While headline data suggests resilience, much of the economy is running at a far slower pace. Discou…
For investors seeking momentum, State Street SPDR S&P Pharmaceuticals ETF XPH is probably on the radar. The fund just hit a 52-week high and rose 61.4% from its 52-week low price of $35.22/share. But, are more gains in store for this ETF?…
Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market. An increasingly popula…
With a market cap of $1 trillion, Eli Lilly and Company (LLY) is one of the world’s leading pharmaceutical innovators, known for developing breakthrough medicines in metabolic diseases, oncology, neuroscience, and immunology. Founded in 18…
[Close-up of a male hand holding a pill bottle pouring medication into his hand] Trevor Williams The recent news [https://seekingalpha.com/news/4525254-novo-nordisk-slides-as-ozempic-pill-fails-to-slow-alzheimers-disease-progression-in-lar…
The third-quarter results of the broader Medical sector, which includes major large-cap pharmaceutical companies, have been quite impressive this year, with more than 82% of sector participants having reported so far. These stocks posted a…
21 out of 60 S&P 500 health care companies reported quarterly results this week, of which 20 delivered an earnings beat, and one came in-line with estimates. 16 of the reporting companies exceeded revenue consensus, while five trailed expe…